3 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 3 | 1 | Completed 1 |
Follow CCTU: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FOLFOXIRI With or Without Intensification for Rectal Cancer Control arm, Experimental arm - Rectal Cancer | Phase 2 | Active not recruiting | CCTU | 72 | 2019-09-10 | 2025-11-17 |
| SRAM study_Postate Cancer Conventional IMRT, SBRT - Advanced Prostate Cancer | Phase 2 | Active not recruiting | CCTU | 120 | 2019-05-15 | 2026-03-04 |
| Pembrolizumab in Hepatocellular Carcinoma pembrolizumab - HCC | Phase 2 | Active not recruiting | CCTU | 30 | 2018-04-30 | 2026-03-04 |
| Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients Experimental drug: Aprepitant, Experimental drug: Ondansetron, Experimental drug: Dexamethasone - Breast Cancer | Phase 3 | Completed | CCTU | 120 | 2017-03-23 | 2021-07-28 |
Breast Neoplasms (1) · Rectal Neoplasms (1)
pembrolizumab (1)
Hong Kong (4)